Lisanti Capital Growth LLC reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 44.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,510 shares of the biopharmaceutical company’s stock after selling 51,024 shares during the period. Lisanti Capital Growth LLC […]
Lisanti Capital Growth LLC reduced its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 44.5% during the first quarter, Holdings Channel.com reports. The firm owned 63,510 shares of the biopharmaceutical company’s stock after selling 51,024 shares during the period. Lisanti Capital Growth LLC’s holdings in Intra-Cellular Therapies were worth $3,439,000 as […]
Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $73 00 at Needham & Company LLC kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective increased by UBS Group from $74.00 to $80.00 in a report issued on Friday morning, The Fly reports. ITCI has been the topic of several other research reports. Canaccord Genuity Group upped their price objective on shares of Intra-Cellular Therapies from $93.00 to $98.00 and […]
Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective increased by UBS Group from $74.00 to $80.00 in a report published on Friday, The Fly reports. Other research analysts have also issued research reports about the company. Bank of America lifted their price target on Intra-Cellular Therapies from $62.00 to $63.00 and gave the […]